Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rifapentine - Sanofi

Drug Profile

Rifapentine - Sanofi

Alternative Names: DL 473; L 11473; M000473; MDL 473; Priftin; R 773

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Centers for Disease Control and Prevention; Sanofi; sanofi-aventis
  • Class Antituberculars; Heterocyclic compounds; Piperazines; Rifamycins
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Tuberculosis
  • No development reported Mycobacterium avium complex infections

Most Recent Events

  • 10 Oct 2018 Sanofi plans a trial for Tuberculosis (Combination therapy) in Australia (ACTRN12618001672246p)
  • 07 Aug 2018 Launched for Tuberculosis in Russia (PO)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top